Catalyst Pharmaceuticals

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals was founded in 2002 by Patrick J. McEnany, who has served as Chairman and CEO since inception. The company is headquartered in Coral Gables, Florida, and operates as a publicly traded commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing therapies for rare diseases. The underlying wealth is corporate rather than familial — Catalyst generates revenue through direct drug sales in the US market. Catalyst's strategy centers on acquiring or in-licensing late-stage or already-approved rare-disease drugs and commercializing them through a dedicated internal sales force. The company's lead asset is Firdapse (amifampridine), approved for Lambert-Eaton myasthenic syndrome (LEMS) in adults. In July 2023, Catalyst expanded its portfolio by acquiring the US rights to Agamree (vamorolone), a treatment for Duchenne muscular dystrophy, from Santhera Pharmaceuticals. The firm covers the US and Canada directly, with additional pipeline programs targeting rare neurological and neuromuscular disorders. Confirmed pipeline work includes a sublingual formulation of amifampridine for pediatric LEMS and MuSK-myasthenia gravis. In July 2024, Catalyst acquired Dyne Therapeutics' rare disease portfolio in a deal that brought in two advanced neuromuscular assets, further consolidating its position in the rare disease space (per the firm, July 2024). The company employs a lean commercial model, splitting operations between Coral Gables and a commercial hub in the northeastern US. Its fully internalized sales infrastructure — rather than a royalty-on-partner model — gives Catalyst margin control rarely seen in orphan drug companies with sub-$500 million revenue bases. No separate philanthropic foundation or operating arm is publicly indicated. Catalyst's structural differentiator is its focus on commercial-stage rare-disease acquisitions rather than early-stage R&D risk. Where most rare-disease companies either pursue novel drug discovery or license out their assets to larger pharma partners, Catalyst buys existing approved or near-approval drugs and runs the US commercial engine itself — a model closer to a specialty pharma roll-up than a traditional biotech.